{"filing":{"accession_number":"0001193125-26-391358","cik":"0001691082","ticker":"LBRX","company_name":"LB PHARMACEUTICALS INC","form":"8-K","filing_date":"2026-09-15","report_date":"2026-09-15","primary_document":"d157620d8k.htm","primary_document_url":"https://www.sec.gov/Archives/edgar/data/1691082/000119312526391358/d157620d8k.htm"},"events":[{"id":33486,"run_id":30788,"accession_number":"0001193125-26-391358","anchor_item_number":"5.02","event_type":"exec_appointment","event_domain":"governance","is_material":true,"confidence":0.95,"summary":"LB Pharmaceuticals appointed Susan G. Kozauer, M.D. as Chief Medical Officer, effective September 14, 2026. Dr. Kozauer brings extensive neuropsychiatric drug development expertise and will play a critical role in advancing the company's lead product LB-102 toward Phase 3 NOVA-2 trial results expected in H1 2027. The appointment includes a base salary of $515,000, a sign-on bonus of $150,000, and a 200,000-share option grant.","company_name":"LB PHARMACEUTICALS INC","ticker":"LBRX","filing_date":"2026-09-15","form":"8-K","submitted_at":null,"items":[{"id":36941,"accession_number":"0001193125-26-391358","item_number":"5.02","item_title":null,"event_type":"exec_appointment","event_domain":"governance","is_material":true,"confidence":0.95,"reasoning":"The filing discloses the appointment of Susan G. Kozauer, M.D. as Chief Medical Officer of LB Pharmaceuticals, effective September 14, 2026. While the disclosure includes compensatory details (base salary of $515,000, sign-on bonus of $150,000, and a 200,000-share option grant), the principal disclosed action is the appointment of a named executive officer to a C-suite position. The appointment is material to a reasonable investor given Dr. Kozauer's extensive clinical development expertise and the company's imminent Phase 3 trial readout in schizophrenia.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-09-15T12:07:54.015571+00:00","company_name":"","ticker":null,"filing_date":""},{"id":36942,"accession_number":"0001193125-26-391358","item_number":"7.01","item_title":null,"event_type":"exec_appointment","event_domain":"governance","is_material":true,"confidence":0.95,"reasoning":"The filing discloses the appointment of Dr. Susan G. Kozauer as Chief Medical Officer of LB Pharmaceuticals, effective September 15, 2026. The press release emphasizes her extensive neuropsychiatric drug development expertise and her critical role in advancing the company's lead product LB-102 toward Phase 3 NOVA-2 trial results expected in H1 2027. This is a material executive appointment to a senior officer position at a clinical-stage biopharmaceutical company at a pivotal moment in its development pipeline.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-09-15T12:07:54.015571+00:00","company_name":"","ticker":null,"filing_date":""}]}],"classifications":[{"id":36941,"accession_number":"0001193125-26-391358","item_number":"5.02","item_title":null,"event_type":"exec_appointment","event_domain":"governance","is_material":true,"confidence":0.95,"reasoning":"The filing discloses the appointment of Susan G. Kozauer, M.D. as Chief Medical Officer of LB Pharmaceuticals, effective September 14, 2026. While the disclosure includes compensatory details (base salary of $515,000, sign-on bonus of $150,000, and a 200,000-share option grant), the principal disclosed action is the appointment of a named executive officer to a C-suite position. The appointment is material to a reasonable investor given Dr. Kozauer's extensive clinical development expertise and the company's imminent Phase 3 trial readout in schizophrenia.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-09-15T12:07:54.015571+00:00","company_name":"LB PHARMACEUTICALS INC","ticker":"LBRX","filing_date":"2026-09-15"},{"id":36942,"accession_number":"0001193125-26-391358","item_number":"7.01","item_title":null,"event_type":"exec_appointment","event_domain":"governance","is_material":true,"confidence":0.95,"reasoning":"The filing discloses the appointment of Dr. Susan G. Kozauer as Chief Medical Officer of LB Pharmaceuticals, effective September 15, 2026. The press release emphasizes her extensive neuropsychiatric drug development expertise and her critical role in advancing the company's lead product LB-102 toward Phase 3 NOVA-2 trial results expected in H1 2027. This is a material executive appointment to a senior officer position at a clinical-stage biopharmaceutical company at a pivotal moment in its development pipeline.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-09-15T12:07:54.015571+00:00","company_name":"LB PHARMACEUTICALS INC","ticker":"LBRX","filing_date":"2026-09-15"}]}